30
Participants
Start Date
March 22, 2022
Primary Completion Date
February 28, 2027
Study Completion Date
February 28, 2037
CD4^LVFOXP3
"Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood."
RECRUITING
Lucile Packard Children's Hospital, Palo Alto
California Institute for Regenerative Medicine (CIRM)
OTHER
Bacchetta, Rosa, MD
OTHER